key: cord-0954478-je38qw0c
authors: Fischer, Robert J.; van Doremalen, Neeltje; Adney, Danielle R.; Yinda, Claude Kwe; Port, Julia R.; Holbrook, Myndi G.; Schulz, Jonathan E.; Williamson, Brandi N.; Thomas, Tina; Barbian, Kent; Anzick, Sarah L.; Ricklefs, Stacy; Smith, Brian J.; Long, Dan; Martens, Craig; Saturday, Greg; de Wit, Emmie; Gilbert, Sarah C.; Lambe, Teresa; Munster, Vincent J.
title: ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease
date: 2021-03-15
journal: bioRxiv
DOI: 10.1101/2021.03.11.435000
sha: 16b1011c2e29606577edd1b31ecbe068d8532d76
doc_id: 954478
cord_uid: je38qw0c

We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals did not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus was detected in lungs of vaccinated animals. Histopathological evaluation showed extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.

- Table 1 nor SARS-CoV-2 antigen was found in lungs of vaccinated animals, but both were abundantly 117 present in lungs of control animals (Figure 1g ,h, p=0.0286, Mann-Whitney test). Finally, 118 105 and is also made available for use under a CC0 license.

(which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC The copyright holder for this preprint this version posted March 15, 2021. ; https://doi.org/10.1101/2021.03.11.435000 doi: bioRxiv preprint oropharyngeal swabs were collected on 1 to 5 DPI, evaluated for sgRNA, and an area under the 119 curve was calculated per animal to determine the cumulative amount of virus shed. We observed 120 a decrease in the total amount of respiratory shedding for both vaccinated groups compared to 121 control animals, although this was statistically significant for B.1.1.7 only (Figure 1i according to the manufacturer's instructions and following high containment laboratory 360 protocols. A viral sgRNA 26 specific assay was used for the detection of viral RNA. Five μL of 361 extracted RNA was tested with the Quantstudio 3 system (Thermofisher) according to 362 instructions from the manufacturer. A standard curve was generated during each run using 363 SARS-CoV-2 standards containing a known number of genome copies.

Viral RNA sequencing 365 For sequencing from viral stocks, sequencing libraries were prepared using Stranded Total RNA

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in